9,848 Shares of Cencora, Inc. $COR Bought by Vise Technologies Inc.

Posted by George Bondi on Nov 5th, 2026

Vise Technologies Inc. bought a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,848 shares of the company’s stock, valued at approximately $2,957,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Cidel Asset Management Inc. grew its stake in Cencora by 6.9% during the 3rd quarter. Cidel Asset Management Inc. now owns 1,262 shares of the company’s stock worth $379,000 after buying an additional 81 shares during the last quarter. Avestar Capital LLC purchased a new position in shares of Cencora during the third quarter worth approximately $343,000. State of Wyoming purchased a new position in shares of Cencora during the third quarter worth approximately $271,000. Raleigh Capital Management Inc. increased its holdings in shares of Cencora by 8.5% in the 3rd quarter. Raleigh Capital Management Inc. now owns 753 shares of the company’s stock valued at $226,000 after acquiring an additional 59 shares during the period. Finally, Brian Low Financial Group LLC increased its holdings in shares of Cencora by 5.2% in the 3rd quarter. Brian Low Financial Group LLC now owns 6,171 shares of the company’s stock valued at $1,853,000 after acquiring an additional 304 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Up 4.0%

NYSE:COR opened at $354.20 on Thursday. The firm has a market cap of $67.59 billion, a P/E ratio of 26.31, a PEG ratio of 1.74 and a beta of 0.58. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The stock’s 50 day simple moving average is $324.60 and its 200-day simple moving average is $317.44. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported $4.66 EPS for the quarter, topping the consensus estimate of $4.58 by $0.08. The company had revenue of $88.35 billion during the quarter, compared to analysts’ expectations of $87.95 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. The business’s revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the business earned $3.84 EPS. Equities analysts anticipate that Cencora, Inc. will post 17.88 EPS for the current year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Friday, November 13th will be paid a dividend of $0.66 per share. This is an increase from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s payout ratio is 17.83%.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

Positive Sentiment: Fiscal Q4 adjusted EPS of $4.66 beat the $4.58 consensus, while revenue of $88.35 billion topped estimates of $87.95 billion and rose 5.5% year over year. Cencora also reported higher earnings than a year earlier. Article: Cencora Q4 Earnings & Revenues Beat on Specialty Growth, Margins Expand
Positive Sentiment: The company forecast fiscal 2027 EPS of $19.40–$19.75, with specialty growth supporting its outlook. The guidance gives investors an indication of continued earnings growth. Article: Cencora outlines fiscal 2027 EPS outlook
Positive Sentiment: Cencora raised its quarterly dividend 10%, from $0.60 to $0.66 per share, signaling increased cash returns to shareholders. Company dividend information
Neutral Sentiment: Cencora is reorganizing its reporting structure to improve focus and visibility. The change may help execution, though the new structure itself does not establish a near-term financial benefit. Article: Cencora announces new organizational and reporting structure
Neutral Sentiment: Management’s earnings-call discussion was broadly positive but included mention of headwinds; the provided coverage does not detail their size or likely effect on results. Article: Cencora earnings call highlights specialty growth and headwinds

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares in the company, valued at $6,305,754.60. The trade was a 36.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.38% of the company’s stock.

Analyst Upgrades and Downgrades

COR has been the subject of several research reports. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $330.00 price target on shares of Cencora in a research report on Tuesday, September 8th. Robert W. Baird raised their price objective on shares of Cencora from $373.00 to $375.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Wells Fargo & Company lifted their price objective on shares of Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. JPMorgan Chase & Co. upped their target price on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, Citigroup reaffirmed a “buy” rating on shares of Cencora in a report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $368.38.

Get Our Latest Stock Report on COR

Cencora Profile

(Free Report)

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.